Vaxart, Inc.: Revision history

20 August 2022

• curprev 23:0623:06, 20 August 2022 95.149.241.133 talk 826 bytes +11 No edit summary undo

14 August 2022

• curprev 11:3111:31, 14 August 2022 109.180.50.163 talk 815 bytes +15 No edit summary undo

31 July 2022

• curprev 16:5016:50, 31 July 2022 >Chris 800 bytes +800 Created page with "Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza..."